Revolution Medicines · 10 hours ago
Senior Director, Epidemiology
United States
Full-time
Remote
Director/Executive
$244K/yr - $305K/yr
12+ years expRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies. The Senior Director, Epidemiology is responsible for leading the strategy and execution of epidemiology plans and activities, working across various teams to oversee key epidemiology deliverables and contribute to the advancement of oncology through innovative real-world evidence.
Health CareLife ScienceMedical
Responsibilities
Lead the epidemiology strategy for a given asset and/or indication, including developing plans for epidemiology deliverables (e.g., systematic literature reviews, natural history studies, clinical trial design and optimization, comparative effectiveness and safety, post-approval safety studies, and healthcare resource utilization analyses)
Designs and executes deliverables in accordance with the plan, either personally or through oversight of other epidemiologists/vendors/contractors; this may involve the development of templates and SOPs, as well as authoring protocols, SAPs, clinical study reports, slide decks, abstracts, posters, and peer-reviewed manuscripts
Provides epidemiology leadership to Clinical Development, Global Patient Safety, Regulatory Affairs, Medical Affairs, and Commercial activities across the medicines development life cycle. Active participation on cross-functional teams. Lead sub-team meetings as appropriate
Ensures epidemiology point of view is included in key deliverables from other functions such as clinical trial protocols, SAPs, case report forms, regulatory submissions and payer interactions within assigned indications and/or therapeutic areas
Lead activities related to scientific manuscripts, clinical conference abstracts, presentations, and posters based on observational study data
Represents HEOR/RWE department during interactions with key external stakeholders including Scientific Advisory Boards and regulatory authorities
Appraises and synthesizes relevant epidemiological and RWE literature and regulatory guidance documents
Qualification
Required
PhD / DSc / DrPH in epidemiology or a relevant advanced science degree with and at least 12 years of related industry experience at a sponsor/pharmaceutical company
Demonstrated technical knowledge of pharmacoepidemiologic methods and real-world oncology data sets as well as the use of appropriate biostatistical methods
History of publications demonstrating the successful design, execution and communication of epidemiologic research
Knowledge of drug and clinical development process for genomic/targeted medicines
Excellent analytic and problem-solving skills
Excellent attention to detail and quality, and scientific rigor
Strong interpersonal skills and the ability to work effectively in multidisciplinary teams, including ability to provide oversight to vendors
Existing external relationships to foster collaborative and timely research
Preferred
12+ years of oncology pharmacoepidemiology experience at a sponsor/pharmaceutical company
Experience driving from conception to completion post-approval safety studies using RWD submitted to global regulators
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
Pharmaceutical Technology
2026-01-13
Company data provided by crunchbase